Morgan Stanley analyst Sean Laaman has maintained their bullish stance on BMRN stock, giving a Buy rating on August 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors that highlight BioMarin Pharmaceutical’s strong performance and promising future prospects. The company reported a significant revenue beat for the second quarter, particularly in its enzyme therapy franchise, which surpassed both Morgan Stanley’s estimates and consensus expectations. This robust performance led to an upward revision in the company’s revenue guidance for the year, signaling confidence in continued growth.
Additionally, the positive data from the BMN 333 study, which showed promising pharmacokinetic results, is expected to drive further appreciation in BioMarin’s stock. The anticipation of a pivotal Phase 2/3 study beginning in the first half of 2026 further supports the potential for future success. These factors combined suggest a favorable outlook for BioMarin, justifying the Buy rating assigned by Sean Laaman.
In another report released on August 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $66.00 price target.